TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Immunoadsorption for Treatment of Alzheimer's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 55-85 years of age~* Diagnosis of Alzheimer's disease~* Presence of agAAB against alpha1-adrenoceptor~* Mini mental state examination (MMSE) score between 19 and 26~* Written informed consent given~Exclusion Criteria:~* Haemanalysis:~  * Presence of autoantibodies against the N-methyl-D-aspartate (NMDA) receptor~ * Defective blood coagulation at time of inclusion~ * Severe protein deficiency disorders~ * manifest Vitamin/Folic acid deficiency (substitution allowed)~* Active infectious disease, or signs of ongoing infection with C-reactive protein (CRP) \>10mmol/L~* Impaired renal function (serum creatinine \>220 μmol/L)~* Any disease requiring immunosuppressive drugs or therapeutic antibodies~* Non curative treated malignant disease or another life-threatening disease with poor prognosis (survival less than 2 years), except for basal-cell carcinoma~* Unstable angina pectoris, atrioventricular block (AV block) 2./3. degree or symptomatic sick sinus syndrome without implanted pacemaker, history of myocardial infarct, bypass or other revascularization measures, valvular heart defect (≥ 2. Degree)~* Severely reduced left ventricular systolic function (LVEF \< 30%) and/or heart failure symptoms according to New York Heart Association (NYHA) class III/IV~* Clinical manifestation of arterial disease, vascular surgery: No Arteria Carotis Interna (ACI) Stenosis \> 60%, peripheral artery occlusive disease (PAOD) \> IIb, NASCET, no clinical manifest apparent stroke in anamnesis, MRI: no diffusion disorder, no expired territorial stroke~* Endocrine disorder excluding diabetes mellitus~* Severe hepatic damages (CHILD-Score \< 4)~* Severe mental disorders (bipolar disorder, schizophrenia, depression) requiring treatment~* Alcohol or drug abuse~* Drug therapy against dementia since less than 3 months~* Psychopharmacological drug therapy since less than 3 months~* Dialysis requirement~* MRI contraindications (e.g. heart pacemaker)~* Legal tutelage~* Previous treatments with IA or immunoglobulin~* Inability to undergo the study procedure (IA on five consecutive days with subsequent Immunoglobulin G (IgG) substitution)~* treatment with angiotensin-converting-enzyme inhibitors (ACE inhibitors) during the IA (angiotensin receptor blockers (AT-blockers) possible)~* Participation in any other clinical/interventional study within less than 30 days prior to screening date

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Immunoadsorption with Globaffin for Alzheimer Dementia (Type: EXPERIMENTAL): Immunoadsorption with Globaffin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Diagnosis of Chronic Endometritis in Endometrial Fluid Using Molecular Techniques to Improve the Outcomes of Assisted Reproductive Treatments

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who provide their written informed consent after having been informed of the all study aspects.~* IVF or ICSI cycles with own oocytes, with blastocyst transfer (day 5 or 6 of stage development).~* Women with age comprised between 18 and 38 years (both included).~* Body mass index: 18.5 - 30 km/m2 (both included)~* Adequate ovarian reserve \> 8 antral follicles (RFA) and/or Antimüllerian hormone (HAM)\> 1 ng / mL.~* Concentration of spermatozoa \> 2 million sperm/ml.~Exclusion Criteria:~* Congenital or acquired uterine pathologies.~* Endometriosis.~* Patients with IUDs in the last 3 months.~* Patients who have taken prescribed antibiotic treatment in the last 3 months.~* Any disease or medical condition that could be unstable or could endanger the security of the patient and her compliance in the study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 38 Years
- Healthy Volunteers: t

Study Arms:
- Patients with RIF (Type: None): Patients with repeated implantation failure (RIF) with indication of hysteroscopy within normal clinical practice, who will undergo FIV or ICSI and embryo transfer within their assisted reproduction treatment (ART).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: IMT for Primary Clostridium Difficile Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diarrhea as defined by the World Health Organization (passage of 3 or more loose or liquid stools (i.e. taking the shape of the receptacle or corresponding to Bristol stool chart types 5-7) per day, or more frequently than is normal for the individual, and~* Positive fecal test for toxigenic Clostridium difficile, and~* No evidence of CDI during the previous year.~Exclusion Criteria:~* Known presence of other stool pathogens known to cause diarrhea.~* Pregnancy and nursing.~* Patients with ongoing antibiotic treatment for other infections that cannot be stopped for at least 12 hours.~* Inflammatory bowel disease.~* Patients incapable of providing informed consent.~* Patients with \<3 months life expectancy.~* Serious immunodeficiency caused by chemotherapy or other medication.~* Active immunocompromising disease.~* Patients unable to comply with protocol requirements.~* Patients in need of intensive care who are American Society of Anesthesiologists (ASA) Physical Status classification IV and V.~* Known hypersensitivity to Metronidazole

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intestinal microbiota therapy (Type: EXPERIMENTAL): The patients allocated to this group will receive 60 ml of the anaerobically cultivated human intestinal microbiota through a rectal catheter.
- Metronidazole (Type: ACTIVE_COMPARATOR): The patients allocated to this group will receive metronidazole 400 mg t.i.d. for 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic Study of Milrinone in Babies With Persistent Pulmonary Hypertension of the Newborn

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Gestational age \> 34 weeks~* Post-natal age \< 10 days~* Hypoxemia defined by: Oxygenation Index (OI) \>15 (Mean Airway Pressure x Fraction of Inspired Oxygen (FiO2) x 100 /PaO2) as drawn from two post-ductal arterial blood gas samples (in-dwelling arterial catheter) taken at least 15 minutes apart. OR mechanically ventilated and with \>75% FiO2 for \>6 hours while on iNO~* Absence of congenital heart disease based on a two-dimensional echocardiogram and/or clinical assessment~* An in-dwelling arterial catheter to facilitate painless sampling~* Currently on iNO or plan to start iNO before enrollment~Exclusion Criteria:~* Lethal non-cardiac congenital anomalies including diaphragmatic hernia~* Clinically apparent bleeding; thrombocytopenia \<30,000 or other laboratory evidence of coagulopathy~* Currently on extracorporeal membrane oxygenation (ECMO)or plan to initiate ECMO within 2 hours of enrollment

- Gender: ALL
- Minimum Age: None
- Maximum Age: 10 Days
- Healthy Volunteers: f

Study Arms:
- High Dose Milrinone (Type: EXPERIMENTAL): Subjects will receive a bolus intravenous (IV) infusion of 50 mcg/kg/min of milrinone lactate over 1 hour followed by a continuous IV infusion of 0.5 mcg/kg/min milrinone lactate over 24 hours. After completion of infusion, subjects will be monitored for an additional 24 hours.
- Low Dose Milrinone (Type: EXPERIMENTAL): Subjects will receive a bolus intravenous (IV) infusion of 20 mcg/kg/min of milrinone lactate over 1 hour followed by a continuous IV infusion of 0.2 mcg/kg/min milrinone lactate over 24 hours. After completion of infusion, subjects will be monitored for an additional 24 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pain Medication After Ambulatory Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~All plenipotentiary patients, operated as ambulatory surgery patients in our clinic during the study period, with informed consent~Exclusion Criteria:~We do not accept patients, who are not plenipotentiary (minor, incompetent, prisoners, conscript in military service) or do not understand finnish or swedish written information

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Current practice group (Type: None): All plenipotentiary ambulatory surgery patients, with informed consent, during the three month study period
- Standard operating protocol group (Type: None): All plenipotentiary ambulatory surgery patients, with informed consent, during the three month study period after creating and informing standardized operating protocol
- Mobile phone app group (Type: None): All plenipotentiary ambulatory surgery patients during the three month study period with informed consent to use mobile phone app in assesment of pain and pain medication

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of a Lower Limb Strength Training Program on a Seated Robotic Device in Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Acquired Brain Injury of vascular, traumatic, infectious or tumoral origin in the subacute phase~* Walking ability ≤ Functional Ambulatory Category level 5 (1-6)~* Paresis of the lower limb: strength \<57/100 on the Motricity Index~* Cognitive and memory functions allowing the patient to follow treatment instructions and give informed consent~Exclusion Criteria:~* Significant heart problem~* Venous thrombosis less than 6 months~* Musculoskeletal impairment not compatible with movement~* Degenerative neurological disease~* Oxygen-dependent~* Blood pressure not stabilized

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- intervention group (Type: EXPERIMENTAL): group focus on lower limb strength training with a seated robotic device
- control group (Type: ACTIVE_COMPARATOR): physiotherapy group as usual, not focused on strength training

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Catheter-Related Early Thromboprophylaxis With Enoxaparin (CRETE) Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~1. Untunneled CVC inserted in the internal jugular or femoral vein within the past 24 hours~2. Child anticipated to stay in the pediatric intensive care unit ≥48 hours~3. CVC anticipated to be required for ≥24 hours~4. \>36 weeks corrected gestational age to \<18 years old~Exclusion Criteria~1. Coagulopathy (i.e., international normalized ratio \>2.0, activated partial thromboplastin time \>50 seconds or platelet count \<50,000/mm3)~2. Known bleeding disorder~3. Clinically relevant bleeding as defined by the International Society on Thrombosis and Hemostasis (i.e., Hb decreased ≥2 g/dl in 24 hours, required medical or surgical intervention to restore hemostasis, or in a critical organ system \[i.e., retroperitoneum, pulmonary, intracranial or central nervous system\])~4. \<60 days from a clinically relevant bleeding as defined above~5. \<7 days after trauma or surgery~6. Anticipated surgery within 48 hours after insertion of the CVC~7. Renal failure (i.e., creatinine clearance \<30 mL/min)~8. Presence of epidural catheter~9. Currently taking an antithrombotic agent (e.g., low molecular weight heparin (LMWH), unfractionated heparin (UFH) at therapeutic doses, Coumadin or aspirin)~10. Radiologically documented DVT at the site of insertion of the CVC in the previous 6 weeks~11. Known hypersensitivity to heparin or its components, including pork products~12. History of heparin-induced thrombocytopenia (HIT) (i.e., positive serotonin release assay)~13. Currently pregnant~14. Currently lactating~15. Prior enrollment in the study~16. Limitation of care

- Gender: ALL
- Minimum Age: None
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Prophylaxis with enoxaparin (Type: EXPERIMENTAL): A clinical nurse will administer enoxaparin subcutaneously \<24 hours after insertion of the central venous catheter and then give enoxaparin subcutaneously every 12 hours until the removal of the catheter.
- Control arm (Type: NO_INTERVENTION): Participants randomized to the control arm will receive no 'placebo' intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Double-blind, Randomized, Controlled Trial of Quetiapine Versus Haloperidol for the Treatment of Delirium

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female age 18 -75 years~* Was admitted in Maharaj Nakhon Chiang Mai hospital~* Was diagnosed by the diagnostic criteria for DSM-IV-TR delirium due to a general medical condition or delirium due to multiple etiologies~* Delirious state (delirium) of the patients was confirmed by using name-assess confusion assessment method (CAM) and assessment of severity with delirium rating scale-revised-98 (DRS-R-98)~* Have a written consent from the legal representatives~Exclusion Criteria:~* Was diagnosed substance withdrawal delirium~* Having a history drug allergy either from quetiapine or haloperidol~* Female patients who are pregnant or breastfeeding~* No written consent from the legal representatives~* Received other anti-psychotic drug before attend the study~* Being ill with renal or hepatic failure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- quetiapine (Type: EXPERIMENTAL): atypical antipsychotic drug
- haloperidol (Type: ACTIVE_COMPARATOR): typical antipsychotic drug

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Chronic Post-Traumatic Headache With OnabotulinumtoxinA

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of mild traumatic brain injury (mTBI) within the past 15 months~* Suffer at least fifteen total headache days per month~* Ability to speak and read English~Exclusion Criteria:~* Subject with hypersensitivity reactions or other intolerance to OnabotulinumtoxinA~* Previous use of OnabotulinumtoxinA for treatment of headache~* Any medications commonly used as headache preventives started less than 3 months prior to enrollment~* Prior or current diagnosis of major psychiatric disorder or other central nervous system disorder~* Less than 80% compliance (recorded for less than 24 days) in the 30 day screening headache diary~* Subjects who are pregnant or trying to become pregnant within the timeframe of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Treatment with OnabotulinumtoxinA (Type: EXPERIMENTAL): OnabotulinumtoxinA

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Differential Efficacy of Corticosteroid Solutions for Non-Operative Treatment of Digit Flexor Tenosynovitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Adults aged 18 years and older~2. At least one symptomatic trigger finger~3. Patients recommended to receive corticosteroid injections~Exclusion Criteria:~1. Previous surgeries/injections for trigger fingers in digit being treated for study~2. Participating in another clinical trial~3. Inability to receive corticosteroid injections (i.e. allergies, adverse reactions, etc.)~4. Unable to sign informed consent~5. Pregnant or plan to become pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Triamcinolone 40mg/mL (Type: ACTIVE_COMPARATOR): A corticosteroid injection of Triamcinolone 40mg/mL will be given to subjects to treat their symptoms of trigger finger.
- Triamcinolone 10mg/mL (Type: ACTIVE_COMPARATOR): A corticosteroid injection of Triamcinolone 10mg/mL will be given to subjects to treat their symptoms of trigger finger.
- Soluble dexamethasone 4mg/mL (Type: ACTIVE_COMPARATOR): A corticosteroid injection of Soluble Dexamethasone 4mg/mL will be given to subjects to treat their symptoms of trigger finger.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: EXOme Rare Cancers in Children (EXOCARE)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* For Patient cancer :~  * Child having developed a cancer combined with a delay of development and\\or an intellectual deficiency before the age of 18 years and followed for a cancer of the child in one of hospital center of the Société Française de lutte contre les Cancers et les leucémies de l'Enfant et de l'adolescent (SFCE)~ * At least a parent still alive and available to make genetic analyses~* For Parent of cancer patient :~  * Parent whose child meets the criteria of inclusion of Cancer patient~Exclusion Criteria:~* For Cancer patient :~  * Genetic predisposition already identified at the child~ * Absence of histological confirmation~ * Child died without DNA of the available germinal lineage~* For Parent of cancer patient :~  * Parent whose child doesn't meets the criteria of inclusion of Cancer patient

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cancer patient (Type: OTHER): * Collection of blood sample or saliva~* Collection of a tumor sample taken before the participation of the patient in study~* Collection of blood sample if tumor sample is not available
- Parent of cancer patient (Type: OTHER): -Collection of blood sample or saliva

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Master Preceptor Fellowship Program: A Pilot Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Have a medicine or physician assistant degree (MD/DO or PA)~* Be board certified or board eligible in family medicine, general internal medicine, or general -pediatrics; or be certified as a physician assistant~* Have a position in a community-based primary care site~* Have a record of practice in a primary care discipline field for at least two years~* Be at least 18 years of age~Exclusion Criteria:~* Unable to adequately speak and comprehend English~* Less than 18 years of age

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Stepwise Approach To sUbstrate Modification for Ventricular Tachycardia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 to 90 years.~* History of coronary artery disease.~* Presence of, or planned for, an ICD prior to discharge.~* Presentation for management of ICD shock/ATP therapy or monomorphic ventricular tachycardia.~Exclusion Criteria:~* Ventricular arrhythmia not thought to be due to CAD.~* Unstable angina~* CVA within 30 days.~* Protruding left ventricular thrombus or critical aortic stenosis on pre-ablation echocardiography~* Pregnancy~* Any condition resulting in an absolute contraindication to anticoagulation~* Inability to follow-up at ICD clinic.~* Inability to give informed consent.~* Non-inducible for sustained monomorphic ventricular tachycardia.~* Prior substrate guided ablation.~* Definite need for epicardial ablation, as determined by the primary operator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- catheter-based ablation (Type: OTHER): catheter ablation - a medical procedure used to treat some types of arrhythmia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues